The discussion points for this week are as follows:
1. This paper is a retrospective cohort study – what is the place of observational studies in influencing or changing clinical practice?
2. Endpoints measured – where they robust enough to show that beta blockers are safe in COPD in this patient population?
3. The paper used a database of patients in one geographical area. Should we be trying to build up the links needed to produce this kind of data across the UK more generally?
4. Is there a need for prospective research into whether beta blockers are safe in patients with COPD?
You’re quite right on this blog post
This surely makes perfect sense.
What a really good piece…
You could not be more right on..